

**Dr. Shona Milon Nag**

❖ **Education**

**Education at University/Medical School Level.**

| <b>Qualification</b>   | <b>From (year)</b> | <b>To (Year)</b> | <b>Place</b>                  |
|--|--------------------|------------------|-------------------------------|
| M.B.B.S.   | 1982               | 1986             | Pune University               |
| M.D.(General Medicine)   | 1988               | 1990             | Pune University               |
| Fellowship in Medical Oncology, Tata Memorial Hospital/Bombay Hospital | 1993               | 1994             | Bombay University             |
| Fellowship in Medical Oncology   | 1998               | 1999             | University of New South Wales |

❖ **POSITIONS HELD:**

|                     |  |
|---------------------|--|
| 1991 to 1992        | Physician--Intensive Care Unit, Inlaks & Budhrani Hospital, Pune   |
| 1993 to 1994        | Trainee in Medical Oncology, Bombay Hospital Research and Medical Centre, Mumbai   |
| Apr 1994 - Oct 1994 | Trainee in Medical Oncology, Tata Memorial Hospital and Research Centre , Mumbai   |
| 1994                | Trainee Medical Oncologist, Bombay Hospital Research and Medical Centre, Mumbai  |
| 1995-1997           | Junior Consultant Medical Oncologist, M. N. Budhrani Cancer Institute, Pune  |
| 1998 -1999          | Oncology Fellow, Cancer Care Centre, St. George Hospital, Sydney   |
| 1999 - 2002         | Consultant Medical Oncologist, M. N. Budhrani Cancer Institute, Pune   |
| 2002 - 2018         | Consultant Medical Oncologist Jehangir Hospital, Pune<br>Project Director - Oncology Clinical Research JCDC (Jehangir Clinical Development Center) |

**PRESENT POSTIONS:**

- Director Oncology Services, Sahyadri Hospitals, Pune
- Visiting Oncologist, Breast Clinic, KEM Hospital, Mumbai
- Member Ethics Committee, ACTREC (Advanced Centre for Treatment Research and Education in Cancer), Navi Mumbai
- Member Executive Committee ISMPO (Indian Society of Medical and Pediatric Oncology)
- Member at Large, International Quality Steering Group, ASCO

❖ **MEMBERSHIPS/AFFILIATIONS:**

- Indian Society of Hematology and Blood Transfusions.
- ISMPO
- American Society of Clinical Oncology (ASCO).
- European Society of Clinical Oncology (ESCO).
- Collaborative Oncology Network (ICON).
- Has been a member of several DSMBs in the past.

❖ **PUBLICATIONS:**

- 1) Nag S., Pai S. K., Advani S. H., 1995, '**Hepatitis B Viral Infection in ALL**' Indian J. Haem. And Blood Transfusion,' 13:150-3.
- 2) Albain K. S., Nag S., Calderillo-Ruiz G., Jordaan J. P., Llombart A., Pluzanska M A., Pawlicki , Melemed A. S., J. O'Shaughnessy , Reyes J.M., 2004, '**Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival,**' *Journal of Clinical Oncology*, 22:14\_suppl, 510-510
- 3) Wang Y., Raghunadharao D., Raman G., Doval D, Advani S., Julka P., Parikh P., Patil S., Nag S., Madhavan J., Varadhachary A., 2006, '**Adding oral talactoferrin to first-line NSCLC chemotherapy safely enhanced efficacy in a randomized trial,**' *Journal of Clinical Oncology*, 24:18\_suppl, 7095-7095.
- 4) Parikh, Purvish M. 1; Wang, Yenyun 2; Ranade, A A. 3; Vaid, A K. 4; Advani, S H. 5; Raghunadharao, D 6; Nag, S 7; Madhavan, J P. 8; Varadhachary, Atul, September 2- 6, 2007 '**Oral talactoferrin extends survival in patients with refractory NSCLC in a randomized, placebo- controlled, phase 2 trial: C1-05,**' *Journal of Thoracic Oncology. 12th World Conference on Lung Cancer, Seoul, Korea*, . 2(8) Supplement 4:S360, August 2007.
- 5) Dirix L. Y., Ignacio J., Nag S, Bapsy P., Gomez H., Raghunadharao D., Paridaens R., Jones S., Falcon S., Carpentieri M, Abbattista A., Lobelle J. P., '**Treatment of Advanced Hormone-Sensitive Breast Cancer in Postmenopausal Women With Exemestane Alone or in Combination With Celecoxib,**' Mar 10 2008, *Journal of Clinical Oncology* : 1253-1259.

- 6) Julka P. K., Chacko R. T., Nag S., Parshad R., Nair A., Oh D. S., Hu Z., Koppiker C. B., Nair S., Dawar R., Dhindsa N., Miller I. D., Ma D., Lin B, Awasthy B and Perou C, 1 April 2008, **'A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling,'** *British Journal of Cancer* (2008) 98, 1327–1335. (Published online).
- 7) Parikh P., Chang, Yuang-Chi B.M., Nag, S., Digumarti R., Bhattacharyya G. S., Doval D. C., Babu G., Chacko R., Advani S., Ranade A., Aggarwal S., Jagannathan R., Hargreaves L., Thatcher N., April 2008, **'Clinical Experience with Gefitinib in Indian Patients,'** *Journal of Thoracic Oncology*, 3(4):380-385.
- 8) Gomez H. L., Doval D. C., Chavez M. A., Ang P. C., Aziz Z., Nag S., Christina N.G., Sandra X. Franco, Louis W.C. Chow, Arbushites M. C., Michelle A. Casey M. S. Berger, Steven H. Stein, George W. Sledge, Jun 20 2008, **'Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer,'** *Journal of Clinical Oncology*, 2999-3005.
- 9) Albain K. S., Nag S. M., German Calderillo-Ruiz, Jordaan J. P., Antonio C. Pluzanska L. A., Rolski J., Allen S. Melemed, Jose M. Reyes V., Jagdev S. Sekhon, Lorinda Simms, and Joyce O'Shaughnessy, Aug 20 2008, **'Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment,'** *Journal of Clinical Oncology* , 3950–3957.
- 10) Ranade A. A., Bapsy P. P., Nag S., Raghunadharao D., Raina V., Advani S. H., Mishra S. K., Tyagi S., Burman A. C., Parikh P. M. , 2008, **'A novel, cremophor-free, polymeric nanoparticle paclitaxel (do/ndr/02) multicenter study in advanced/ metastatic breast cancer,'** *Journal of Clinical Oncology*, 26:15\_suppl, 1115-1115.
- 11) Friedman S., Levy R., Garrett W., Doval D., Bondarde S., Sahoo T., LokanathaD., Julka P., Shenoy K, Nagarkar R., Bhattacharyya G., Kumar K., Nag S., Mohan P. Narang N., Raghunadharao N., Walia M., YaoW., Li J., Emm T., Yeleswaram S., ScherleP., Newton R., 2009, **'Clinical Benefit of INCB7839, a Potent and Selective Inhibitor of ADAM10 and ADAM17, in Combination with Trastuzumab in Metastatic HER2 Positive Breast Cancer Patients,'** *Cancer Res*, 69 (24\_Supplement): 5056.
- 12) Prabhaskar K., Nag S., Patil S., Parikh P. M., 2011, **'Optimizing management of cancer related anemia,'** *Indian Journal of Cancer*, issue 1, vol 1.
- 13) Parikh P. M., Gupta S, Parikh B, Smruti B. K., Issrani J., Topiwala S., Goswami C., Bhattacharya G. S., Sen T., Sekhon J. S., Malhotra H., Nag S., Chacko R. T., Govind K. B., Raja T., Vaid A. K., Doval D.C., Gupta S., Das P.K., Apr-Jun 2011, **'Management of primary and metastatic triple negative breast cancer: perceptions of oncologists from India'** *Indian J Cancer* .,48(2):158-64.
- 14) Digumarti R., Wang Y., Raman G., Doval D. C., Advani S. H., Julka P. K., Parikh P. M., Patil S., Nag S., Madhavan J., Bapna A., Ranade A. A., Varadhachary A., Malik R., June 2011, **'A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer,'** *J Thorac Oncol* .,6(6):1098-103.
- 15) Gupta S., Badwe R. A., Mitra I., Nag S., Dawood S. Munshi A., 2011, **'ES5-1: Breast Cancer Trials in Developing Countries - Opportunities and Challenges,'** *Cancer Res.*, 71 (24\_Supplement): ES5-1.

- 16) Nag S., Apr 2012 '**mTOR inhibition in management of advanced breast cancer,**' *Indian J Med Paediatr Oncol.*, 33(2):89-94.
- 17) Gupta S., Nag S., Dawood S., 2012, '**Challenges and opportunities in the design and implementation of breast cancer clinical trials in developing countries,**' *Clin. Invest.* 2(6), 579–587.
- 18) Dirix L.Y., Ignacio J., Nag S., Bapsy P., Gomez H., Raghunadharao D., Paridaens R., Jones S., Falcon S., Massimini G., 2012 '**Final results from an open-label, multicenter, controlled study of exemestane +/- celecoxib in postmenopausal women with advanced breast cancer (ABC) progressed on tamoxifen,**' *American society of clinical oncology*, 2003, 22, 20. (Online Publication).
- 19) Ranade A. A., Bapsy P. P., Nag S., Raghunadharao D., Raina V., Advani S. H., Patil S., Maru A., Gangadharan V. P., Goswami C., Sekhon J. S., Sambasivaiah K., Parikh P., Bakshi A., Mohapatra R., June 2013, '**A multicenter phase II randomized study of Cremophor-free polymeric nanoparticle formulation of paclitaxel in women with locally advanced and/or metastatic breast cancer after failure of anthracycline,**' *Asia Pac J Clin Oncol.* ,9(2):176-81.
- 20) Saura C., Tseng L.M., Chan S., Chacko R. T., Campone M., Manikhas A., Nag S. M., Leichman C. G., Dasappa L., Fasching P. A., Mendoza F.H., Symmans W. F., Liu D., Mukhopadhyay P., Horak C., Xing G., Pusztai L., 2013, '**Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of  $\beta$ III-tubulin expression as a predictive marker,**' *Oncologist.*, 18(7):787-94.
- 21) Julka P. K., Chacko R. T., Nag S., Parshad R., Nair A., Koppiker C. B., Xue F. C. R., Barraclough H., Dhindsa N., Seth A., Majumdar A., Puri T., Oct 2013, '**A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up,**' *Breast Cancer*, 20(4):357-62.
- 22) Govind Babu K. G., Prabhash K., Vaid A. K., Sirohi D., Diwakar R. B., Rao R., Kar M., Malhotra H., Nag S., Goswami S., Raina V., Mohan R., June 2014, '**Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non- small-cell lung cancer: a multicenter, randomized, open-label Phase II study,**' *Onco Targets Ther.* 13;7:1051-60.
- 23) Nag, S., Mane, A., Gupta.S, 2014, '**Emerging Prognostic and Predictive Biomarkers for Triple Negative Breast Cancer,**' *Curr Breast Cancer*, Rep 6, 275–282.
- 24) Mane A., Khatib K. I., Deshmukh S. P., Nag S. M., Sane S. P., Zade B. P., Sep. 2015, '**A Comparison of Clinical Features, Pathology and Outcomes in Various Subtypes of Breast Cancer in Indian Women,**' *J Clin Diagn Res.*, 9(9):PC01-4.
- 25) Nag S., Sinukumar S., Hegde S., 2017, "**Germline Testing for Predisposition to Breast/Ovarian Cancer Should Only be Offered to Selected Patients with Epithelial Ovarian Cancer**" *Indian J Gynecol Oncolog* 15, 31–36.

- 26) Pai T., Gupta S., Gurav M., Nag S., Shet T., Patil A., Desai S., Jan 24 2018, '**Evidence for the association of Epstein-Barr Virus in breast cancer in Indian patients using in-situ hybridization technique,**' *Breast J.* ,(1):16-22.
- 27) Gupta S., Babu G. K., Chacko R. T., Doval D., Desai C., Kilara N., Nag S. M., Shah C.A., Deo SVS, Koppikar S. B., Swarup B., Kukreja A. A., Raina V., 2018, '**An open label, single arm, prospective phase II study to evaluate the efficacy and safety of bevacizumab with gemcitabine and carboplatin as first-line treatment for metastatic triple negative breast cancer patients,**' *Journal of Clinical Oncology*, 36:15 suppl, 1098-1098.
- 28) Gupta S., Chatterjee S., Nigade J., Aggarwal S., Singhal M., Alurkar S. S., Kukreja A., Smruti B. K. , Nag S., Agarwal A., Agarwal V., Chacko R., Desai C., Goswami C., Keechilat P., Patil P., Krishna P. , Rajendranath R., Rao R. R., Sahoo T. P., Singh A., Singh R., Srinivasan S., Warriar A., Swarup B., Bhattacharya P., Advani S. H., 2018, '**Current Treatment Options for Human Epidermal Growth Factor Receptor 2-Directed Therapy in Metastatic Breast Cancer: An Indian Perspective,**' *Indian J Med Paediatr Oncol*, 39(03): 368-379.
- 29) Gupta S., Nag S., Aggarwal S., Rauthan A., Warriar N., Nov 4 2019, '**Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review,**' *J Ovarian Res.*, 12(1):103.
- 30) Vaid A. K., Gupta S., Doval D. C., Agarwal S., Nag S., Patil P., Goswami C., Ostwal V., Bhagat S., Patil S., Barkate H., Mar 27 2020, '**Expert Consensus on Effective Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective,**' *Front Oncol.*, 10:400.
- 31) D'Souza R. B., Ghose J. D., Nag S.M., Aug 2021, '**Breast cancer survivorship in India,**' *Indian J Med Res.*, 154(2):177-179.
- 32) Nag S. , Sep-Oct 2021, '**Duration of trastuzumab use in patients with early breast cancer,**' *Natl Med J India.* , 34(5):285-286.
- 33) Kulkarni R., Kulkarni S., Pathan A., Nag S., 2021, '**A Retrospective analysis of biosimilar and reference trastuzumab in human epidermal growth factor receptor-2 positive early and/or locally advanced breast cancer patients treated with neoadjuvant-adjuvant setting: Safety and event-free survival outcomes,**' *Oncology Journal of India*, 5(3), p 97-103.

❖ **EXPERIENCE IN CLINICAL TRIALS**

After returning from Australia in 1999, set up Clinical Trials Units, both at Inlaks and Budhrani Hospital as well as at Jehangir Hospital.

Principal Investigator for over 60 Phase I, II, III global clinical trials

| CLINICAL TRIAL INDICATION | NUMBER OF TRIALS CONDUCTED<br>(2000 till PRESENT) |
|---------------------------|---|
|---------------------------|---|

